These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 37864239)
1. Ten-year radiographic and functional outcomes in rheumatoid arthritis patients in remission compared to patients in low disease activity. Ruyssen-Witrand A; Guernec G; Dupont J; Lapuyade D; Lioté F; Vittecoq O; Degboé Y; Constantin A Arthritis Res Ther; 2023 Oct; 25(1):207. PubMed ID: 37864239 [TBL] [Abstract][Full Text] [Related]
2. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes. Ruyssen-Witrand A; Guernec G; Nigon D; Tobon G; Jamard B; Rat AC; Vittecoq O; Cantagrel A; Constantin A Ann Rheum Dis; 2015 Sep; 74(9):1676-83. PubMed ID: 24794151 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234 [TBL] [Abstract][Full Text] [Related]
4. Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1 year who achieved clinical remission or low disease activity. Hattori Y; Kida D; Kaneko A Clin Rheumatol; 2017 Nov; 36(11):2607-2612. PubMed ID: 28823077 [TBL] [Abstract][Full Text] [Related]
5. Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy. Hirano F; Yokoyama W; Yamazaki H; Amano K; Kawakami A; Hayashi T; Tamura N; Yasuda S; Dobashi H; Fujii T; Ito S; Kaneko Y; Matsui T; Okuda Y; Saito K; Suzuki F; Yoshimi R; Sakai R; Koike R; Kohsaka H; Miyasaka N; Harigai M; Mod Rheumatol; 2017 Sep; 27(5):811-819. PubMed ID: 27919205 [TBL] [Abstract][Full Text] [Related]
6. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720 [TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment. Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837 [TBL] [Abstract][Full Text] [Related]
8. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491 [TBL] [Abstract][Full Text] [Related]
9. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. Strand V; Lee EB; Yazici Y; Dikranian A; Wilkinson B; Takiya L; Zang C; Bananis E; Bergman MJ Clin Rheumatol; 2018 Aug; 37(8):2043-2053. PubMed ID: 29656373 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE; Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230 [TBL] [Abstract][Full Text] [Related]
13. Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. Smolen JS; Choe JY; Weinblatt ME; Emery P; Keystone E; Genovese MC; Myung G; Hong E; Baek I; Ghil J RMD Open; 2020 Jan; 6(1):. PubMed ID: 31958281 [TBL] [Abstract][Full Text] [Related]
14. Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort. Krams T; Ruyssen-Witrand A; Nigon D; Degboe Y; Tobon G; Fautrel B; Berenbaum F; Cantagrel A; Constantin A Joint Bone Spine; 2016 Oct; 83(5):511-5. PubMed ID: 26992954 [TBL] [Abstract][Full Text] [Related]
15. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185 [TBL] [Abstract][Full Text] [Related]
16. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Hamann PDH; Pauling JD; McHugh N; Shaddick G; Hyrich K; Rheumatology (Oxford); 2019 Dec; 58(12):2162-2169. PubMed ID: 31155669 [TBL] [Abstract][Full Text] [Related]
17. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548 [TBL] [Abstract][Full Text] [Related]
18. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort. Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497 [TBL] [Abstract][Full Text] [Related]
19. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454 [TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]